肝癌靶向治疗的临床研究进展.pdfVIP

Chinese Journal of New Drugs 2010, 19( 17) , ( 中国医学科学院 北京协和医学院肿瘤医院, 北京 100021) [] 原发性肝癌是我国最常见的恶性肿瘤之一, 多数患者就 时已属晚期, 既往传统细胞毒化疗 药对晚期肝癌疗效差近年来, 随着分子生物学的深入研究, 分子靶向药物的临床应用为肝癌的治疗带来了 新突破索拉非尼是 一种口服的多激酶抑制剂, 通过阻断 RAF 信号传导通路及血管内皮生长因子受体 (VEGFR)而抑制肿瘤细胞增殖 期临床研究表明索拉非尼能延长患者生存期, 是首个被批准用于治疗晚 期肝细胞癌的标准药物舒尼替尼和 brivan ib等靶向药物的! ~ ∀期临床试验结果也证明了在晚期肝癌中 的有效性, 期临床研究正在进行中, 期望能给患者提供更多更好的治疗选择 [] 原发性肝细胞癌; 靶向治疗; 临床研究 [] R969. 1 [] A [] 100 - 7 4( 2010) 17- 1547- 04 A dvances in clin ical studies of targeted treatm ent for hepatocellu lar carcinom a L IQ ing, SUN Yan (CancerH osp ital, ChineseA cademy of M edical Sciences, Peking UnionM edical College, Beijing 100021, China) [ Abstract] Hepatocellu lar carcinoma ( HCC) is one ofmost common malignant tumors in Ch ina. Most of patients are in advanced stage at the tmi e of first d iagnosis. Conventional chemotherapy has shown poor effect for advanced HCC. W ith recent yearsprofound research of molecular biology, targeted treatment has appeared as a breakthrough in the treatment of advanced HCC. Sorafen ib is an oralmultip le k inase inh ib itor. It inh ib its tumor an giogenesis through blocking the RAF signaling pathw ay and the activity of vascular endothelial growth factor (VEGF). The phase III clin ical trials show ed that sorafenib, the first m edicine approved to be used in patients w ith unresectableHCC, is able to increase survival of patients. Moreover, phase I~ II trials of targeted med icine such as sun itinib and brivanib has also shown their effectiveness in the treatment of advanced HCC. In the mean tmi e, phase III clin ical study is proceed ing w ith the hope to provide the patientsw ith more and better choices. [K ey w ords] hepatocellular carcinoma; target treatm ent; clin ical trial (, HCC)